Comprehensive analysis of DSP Healthcare Fund (IDCW) (38718) providing detailed insights into fund performance, portfolio holdings, risk metrics, expense ratios, and investment recommendations.
DSP Investment Managers Private Ltd
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. However, there can be no assurance that the investment objective of the scheme will be realized.
A comprehensive at-a-glance view of key mutual fund health indicatorsHover or click any card to view detailed metrics
Weak Returns
High Risk
Moderate Expenses
Equity Focused
Seasoned Team
Below Average
Showing 1Y NAV history
Performance across different time periods
Fund shows concerning indicators. Exercise caution before investing.
Consider waiting for better market conditions or explore alternatives.
Fund shows concerning indicators. Exercise caution before investing.
Consider waiting for better market conditions or explore alternatives.
Historical performance consistency
Market exposure level
Fund manager experience
Recent performance momentum
Assets under management
Risk-adjusted returns
Fund management costs
Outperformance vs benchmark
This fund has outperformed its benchmark by 11.22% over the 3Y period.
See how your money can grow and compare with popular investment options
Disclaimer: Returns are illustrative and based on assumed rates. Mutual fund investments are subject to market risk. Please read scheme documents carefully.
| Company | Sector | % Assets |
|---|---|---|
| Cipla Ltd | Pharmaceuticals | 8.73% |
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals | 8.22% |
| Ipca Laboratories Ltd | Pharmaceuticals | 7.84% |
| Cohance Lifesciences Ltd | Pharmaceuticals | 7.79% |
| Laurus Labs Ltd | Pharmaceuticals | 6.08% |
| Gland Pharma Ltd | Pharmaceuticals | 5.96% |
| Apollo Hospitals Enterprise Ltd | Healthcare | 4.58% |
| Illumina Inc | Debt Others | 4.52% |
| Alembic Pharmaceuticals Ltd | Pharmaceuticals | 4.38% |
| Sai Life Sciences Ltd | Pharmaceuticals | 4.32% |
Compare against Sectoral / Thematic category average
This comparison shows how the fund performs relative to the Sectoral / Thematic category average. Positive values indicate outperformance, while negative values show underperformance.
Compare with similar funds in Sectoral / Thematic category
| Fund Name | NAV | 6M | 1Y | 3Y |
|---|---|---|---|---|
| Aditya Birla SL MNC Fund - Direct (G) | ₹1540.61 | 20.90% | -2.29% | 13.00% |
| Aditya Birla SL MNC Fund - (G) | ₹1383.22 | 20.48% | -2.95% | 12.20% |
| Nippon India Banking&Financial Services-Dir(G) | ₹662.94 | 13.57% | 4.61% | 17.80% |
| Nippon India Banking&Financial Services-Dir(Bonus) | ₹662.94 | 13.57% | 4.61% | 17.80% |
| Nippon India Banking&Financial Services (G) | ₹606.00 | 13.09% | 3.74% | 16.83% |
| Nippon India Banking&Financial Services (Bonus) | ₹606.00 | 13.09% | 3.74% | 16.83% |
| Nippon India Pharma Fund - Direct (G) | ₹574.98 | 13.30% | 0.45% | 24.37% |
| Nippon India Pharma Fund - Direct (Bonus) | ₹574.98 | 13.30% | 0.45% | 24.37% |
| Franklin India Technology Fund - Direct (G) | ₹565.29 | 7.85% | -5.66% | 23.50% |
| ICICI Pru FMCG Fund - Direct (G) | ₹542.41 | 13.18% | -7.36% | 10.35% |
A seasoned investment professional with over 7 years of experience in equity research and fund management. Known for consistent performance and a disciplined investment approach focused on quality growth stocks.